Summary |
|
||||||||
Variant origin |
|
||||||||
Variant description |
|
||||||||
Notes |
Mapping and Phenotype information for this QTL, its variants and associated markersJ:193231To identify genetic determinants of skin cancer susceptibility and carcinoma development, a large backcross population of FVB/NJcl x (FVB/NJcl x MSM/Ms) F1 mice were subjected to DMBA/TPA-induced skin carcinogenesis. MSM/Ms mice are more resistant to chemically induced skin tumor development than the highly susceptible FVB/N strain. (FVB/NJcl x MSM/Ms) male mice were backcrossed with female FVB/NJcl mice generating 121 F1 Tpr53 homozygous mice, p53+/+. Tpr53 deficient male mice (FVB/NJcl x MSM.Cg-Trp53tm1Sia/+) were backcrossed to female FVB/NJcl mice generating 107 Tpr53 heterozygous F1 backcross mice, p53+/-. Mice were genotyped using PCR assays.Tumor development was monitored for a period of 40 weeks; the number of papillomas at 20 weeks as well as the presence of carcinomas at 40 weeks was documented. In addition papillomas were categorized into three groups based on diameter size, 2mm, 2-6mm and 6mm. All mice were genotyped using 107 SNP markers distributed evenly over the genome.In the FVB/NJcl x (FVB/NJcl x MSM/Ms) F1 backcrossed mice the following significant linkages were detected on Chromosome 4:Stmm3a, skin tumor modifier of MSM 3a, a measure of the total number of papillomas >6mm in size at 20 weeks, LOD=5.358 at 44.7 cM. Approximately 73 percent of mice without tumors at this locus were heterozygous with FVB/MSM alleles.Cmmm, carcinoma modifier of MSM, a measure of the total carcinoma at 40 weeks, LOD=4.049 at D4Mit43, 60.3 cM. Sixty nine percent of mice without carcinomas at this locus were heterozygous with FVB/MSM alleles. [Table 1.]In the analysis of combined results from both crosses, 121 FVB/NJcl x (FVB/NJcl x MSM/Ms)F1 mice and 107 (FVB/NJcl x (FVB/NJcl x MSM.Cg-Tpr53 |
||||||||
References |
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 11/12/2024 MGI 6.24 |
|
|